アフターアワーズ： .47 -0.0261 -5.26%

Calidi Biotherapeutics Inc (CLDI)

概要ニュース株価時系列ディスカッション予測

Calidi Biotherapeutics Inc (CLDI) 最新ニュース

Calidi Biotherapeutics Inc (CLDI)

Calidi Biotherapeutics Inc (CLDI) 最新ニュース

ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire

HighTower Advisors LLC Makes New Investment in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire

CLDI stock plunges to 52-week low, hitting $0.57 amid market challenges By Investing.com - Investing.com South Africa

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights - The Manila Times

Calidi Bio Raises Fresh $3.9M Capital to Advance Clinical Programs - Stock Titan

Calidi Biotherapeutics Cuts Losses by 50% While Expanding Cancer Gene Therapy Trials - Stock Titan

CLDI stock plunges to 52-week low, hitting $0.57 amid market challenges - Investing.com India

Virtu Financial LLC Buys Shares of 73,448 Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

Calidi Biotherapeutics sinks after pricing $3.9M registered direct offering - MSN

Calidi prices 3.33M shares at 65c in registered direct offering - TipRanks

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire

Calidi Bio Secures Strategic $3.9M Investment to Accelerate Cancer Immunotherapy Pipeline - Stock Titan

Calidi Biotherapeutics Provides Update On Phase 1 Trial Of CLD-101 For Recurrent Glioma - Nasdaq

Calidi Biotherapeutics and City of Hope Provide Update on a - GlobeNewswire

Calidi Biotherapeutics And City Of Hope Provide Update On A Phase 1 Clinical Trial With CLD-101 Virotherapy In Patients With Recurrent High-Grade Glioma - MarketScreener

Breakthrough Brain Cancer Treatment Advances: 14 Patients Successfully Treated in Groundbreaking Trial - Stock Titan

CLDI stock touches 52-week low at $0.73 amid market challenges - MSN

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Weatherford Democrat

IBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform - Yahoo Finance

Calidi’s Rtnova platform delivers transient gene therapy payloads to tumors - BioWorld Online

Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform - Benzinga

Calidi Biotherapeutics Announces Promising Preclinical Results - TipRanks

Calidi announces ability to deliver transient gene therapy to tumors - TipRanks

Calidi Biotherapeutics Announces Demonstrated Ability To - GlobeNewswire

Calidi Reports Breakthrough: Cancer Platform Kills 60+ Tumor Types - StockTitan

Critical Review: Eloxx Pharmaceuticals (NASDAQ:ELOX) versus Calidi Biotherapeutics (NYSE:CLDI) - Defense World

Calidi Biotherapeutics prices $7.5M secondary offering - MSN

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - WSIL TV

Calidi Biotherapeutics is initiating GMP manufacturing at VetStem BioPharma, a veterinary and human regenerative medicine company in San Diego, CA - ACCESS Newswire

Inside Calidi Biotherapeutics: CFO Andrew Jackson Breaks Down the Future of Oncolytic Virotherapy - Audacy

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth With Strengthened Financial Position And Cutting-Edge Research - MENAFN.COM

Calidi Biotherapeutics Announces Commencement of - GlobeNewswire

Closing Figures Unveiled: Calidi Biotherapeutics Inc (CLDI) Drop -16.67, Closes at 1.05 - The Dwinnex

Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital - The Manila Times

Calidi Biotherapeutics Initiates Recruitment for CLD-101 Clinical Trial Targeting High-Grade Glioma - Nasdaq

Can Multiple Doses Make This Brain Cancer Treatment More Effective? Northwestern Launches Next-Phase Trial - StockTitan

Calidi Biotherapeutics Inc (CLDI) rating initates by H.C. Wainwright - Knox Daily

Taking on analysts’ expectations and winning: Calidi Biotherapeutics Inc (CLDI) - SETE News

CLDI’s 2023 Market Dance: Up 13.04% – Time to Invest? - The InvestChronicle

A review of CLDI’s current quarter earnings predictions - US Post News

What Recent Market Trends Mean for Calidi Biotherapeutics Inc’s (CLDI) Stock - The News Heater

Calidi Biotherapeutics expands stock offering capacity - Investing.com India

Calidi Biotherapeutics expands stock offering capacity By Investing.com - Investing.com South Africa

Market Recap: Calidi Biotherapeutics Inc (CLDI)’s Positive Momentum, Closing at 1.32 - The Dwinnex

For Calidi Biotherapeutics Inc [CLDI], Analyst sees a rise to $11. What next? - The DBT News

Calidi Biotherapeutics Inc Inc. (CLDI) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Get in on Calidi Biotherapeutics Inc’s (CLDI) buy-in window today! - SETE News

Taking a Closer Look At Calidi Biotherapeutics Inc (CLDI) Following Its Recent Trade - Knox Daily

CLDI’s price-to-sales ratio: A comparative analysis with its peers - US Post News

CLDI Stock Plummets to 52-Week Low at $0.6 Amid Market Turbulence - Investing.com Australia

CLDIに似た銘柄